Formycon AG (FYB) - Total Liabilities
Based on the latest financial reports, Formycon AG (FYB) has total liabilities worth €334.23 Million EUR (≈ $390.75 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Formycon AG to assess how effectively this company generates cash.
Formycon AG - Total Liabilities Trend (2009–2024)
This chart illustrates how Formycon AG's total liabilities have evolved over time, based on quarterly financial data. Check FYB asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Formycon AG Competitors by Total Liabilities
The table below lists competitors of Formycon AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Samhi Hotels Limited
NSE:SAMHI
|
India | Rs20.08 Billion |
|
Hospital Mater Dei S.A
SA:MATD3
|
Brazil | R$2.94 Billion |
|
Wheels Up Experience Inc
NYSE:UP
|
USA | $1.36 Billion |
|
Jacquet Metal Service SA
PA:JCQ
|
France | €786.00 Million |
|
Bosung Power Technology Co. Ltd
KQ:006910
|
Korea | ₩29.96 Billion |
|
Clearfield Inc
NASDAQ:CLFD
|
USA | $18.40 Million |
|
TECSYS Inc.
TO:TCS
|
Canada | CA$65.54 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Formycon AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see FYB market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.67 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Formycon AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Formycon AG (2009–2024)
The table below shows the annual total liabilities of Formycon AG from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €309.87 Million ≈ $362.27 Million |
-20.06% |
| 2023-12-31 | €387.61 Million ≈ $453.16 Million |
-22.03% |
| 2022-12-31 | €497.12 Million ≈ $581.18 Million |
+3253.46% |
| 2021-12-31 | €14.82 Million ≈ $17.33 Million |
+96.00% |
| 2020-12-31 | €7.56 Million ≈ $8.84 Million |
+41.51% |
| 2019-12-31 | €5.34 Million ≈ $6.25 Million |
-16.28% |
| 2018-12-31 | €6.38 Million ≈ $7.46 Million |
+20.82% |
| 2017-12-31 | €5.28 Million ≈ $6.18 Million |
+23.03% |
| 2016-12-31 | €4.29 Million ≈ $5.02 Million |
+88.68% |
| 2015-12-31 | €2.28 Million ≈ $2.66 Million |
-30.28% |
| 2014-12-31 | €3.26 Million ≈ $3.82 Million |
+2.22% |
| 2013-12-31 | €3.19 Million ≈ $3.73 Million |
-5.48% |
| 2012-12-31 | €3.38 Million ≈ $3.95 Million |
+639.50% |
| 2011-12-31 | €457.00K ≈ $534.28K |
+118.40% |
| 2010-12-31 | €209.25K ≈ $244.64K |
+243.03% |
| 2009-12-31 | €61.00K ≈ $71.32K |
-- |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more